ArticleEuropean geriatric medicine2025
Diagnostic value of Montreal cognitive assessment combined with olfactory tests for mild cognitive impairment in older adult patients with type 2 diabetes.
Article in European geriatric medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Ketogenic metabolic therapy: low-carbohydrate interventions as novel neuroprotective strategies for cognitive dysfunction in diabetes.Frontiers in aging neuroscience · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
purposeThe study aims to explore the diagnostic value of the Montreal Cognitive Assessment (MoCA) combined with olfactory tests for identifying mild cognitive impairment (MCI) in older adult patients with type 2 diabetes mellitus (T2DM).
methodsThis prospective study enrolled older adult T2DM patients from Jiulongpo District People's Hospital, Chongqing, China, between August 2018 and January 2023. Diagnostic criteria proposed by Petersen served as the gold standard for MCI. The Mini-Mental State Examination (MMSE), MoCA, and olfactory assessments were employed to evaluate cognitive function.
resultsA total of 192 patients were included, of which 94 (49.0%) were diagnosed with MCI (68.5 ± 5.5 years; 31.9% male) and 98 (51.0%) with normal cognitive function (NMCI) (68.4 ± 4.9 years; 45.9% male). Compared to the NMCI group, the MCI group showed significant differences in MMSE (25.6 ± 2.5 vs. 28.7 ± 1.3, P < 0.001), MoCA (20.7 ± 2.5 vs. 26.3 ± 2.4, P < 0.001), olfactory (23.9 ± 7.2 vs. 26.4 ± 8.4, P = 0.027), and olfactory impairment degree (P = 0.004). The area under the ROC curve (AUC) for the olfactory test was 0.620 (95%CI: 0.541-0.699), for MMSE 0.838 (95%CI: 0.779-0.897), and for MoCA 0.948 (95%CI: 0.918-0.977). For the combination of MoCA with olfactory tests, the AUC of the parallel test was 0.955 (95%CI: 0.929-0.982).
conclusionThe MoCA scale is an effective screening tool for MCI in T2DM patients. Additionally, the combination of MoCA and olfactory testing is superior to MoCA alone in identifying MCI in T2DM patients. This combination approach offers a promising diagnostic tool for MCI in T2DM patients.
Indexed as
Identifiers
40304940What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.